

# Rosina T Lis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4903052/publications.pdf>

Version: 2024-02-01

23  
papers

3,704  
citations

471509

17  
h-index

642732

23  
g-index

26  
all docs

26  
docs citations

26  
times ranked

7003  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
2	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5207-E5215.	7.1	266
3	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3705-3715.	1.6	220
4	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017, 23, 2169-2176.	7.0	80
5	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 851-860.	4.7	65
6	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , 2018, 78, 4716-4730.	0.9	56
7	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	1.9	50
8	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 352-359.	1.9	34
9	Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2027-2031.	2.5	28
10	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020, 11, 837.	12.8	28
11	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. <i>European Urology</i> , 2019, 76, 33-40.	1.9	26
12	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	6.4	24
13	Association of Prostate Cancer Risk Variants with <i>TMPPSS2:ERG</i> Status: Evidence for Distinct Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 745-749.	2.5	23
14	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 374-381.	2.8	22
15	Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. <i>Molecular Cancer Research</i> , 2021, 19, 475-484.	3.4	22
16	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	7.0	22
17	MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 201-207.	2.5	21
18	Height, Obesity, and the Risk of <i>TMPPSS2:ERG</i> -Defined Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 193-200.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 3610-3619.	7.0	17
20	Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer—A Pilot Study. <i>Academic Radiology</i> , 2020, 27, 1432-1439.	2.5	9
21	Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. <i>Prostate</i> , 2015, 75, 1926-1933.	2.3	8
22	A Prospective Study of Aspirin Use and Prostate Cancer Risk by <i>TMPRSS2:ERG</i> Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1231-1233.	2.5	2
23	Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. <i>Journal of Urology</i> , 2022, 208, 90-99.	0.4	2